BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 2141506)

  • 1. A novel bioluminescent protease assay using engineered firefly luciferase.
    Wigdal SS; Anderson JL; Vidugiris GJ; Shultz J; Wood KV; Fan F
    Curr Chem Genomics; 2008 Oct; 2():16-28. PubMed ID: 20161840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis: possibilities for therapeutic interventions.
    Wynendaele W; van Oosterom AT; Pawinski A; de Bruijn EA; Maes RA
    Pharm World Sci; 1998 Dec; 20(6):225-35. PubMed ID: 9972522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-signaling targets for antitumour drug development.
    Brunton VG; Workman P
    Cancer Chemother Pharmacol; 1993; 32(1):1-19. PubMed ID: 8384936
    [No Abstract]   [Full Text] [Related]  

  • 4. The inhibitory effect caused by suramin on the paracrine growth of human cancer cells and fibroblasts.
    Mukaida H; Hirabayashi N; Hirai T; Yamashita Y; Iwata T; Saeki S; Toge T
    Surg Today; 1994; 24(3):234-40. PubMed ID: 8003867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.
    Powis G; Seewald MJ; Melder D; Hoke M; Gratas C; Christensen TA; Chapman DE
    Cancer Chemother Pharmacol; 1992; 31(3):223-8. PubMed ID: 1464160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials with anticoagulant and antiplatelet therapies.
    Zacharski LR; Meehan KR; Algarra SM; Calvo FA
    Cancer Metastasis Rev; 1992 Nov; 11(3-4):421-31. PubMed ID: 1423826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
    Bojanowski K; Lelievre S; Markovits J; Couprie J; Jacquemin-Sablon A; Larsen AK
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3025-9. PubMed ID: 1313577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suramin.
    Eisenberger MA; Reyno LM
    Cancer Treat Rev; 1994 Jul; 20(3):259-73. PubMed ID: 8020006
    [No Abstract]   [Full Text] [Related]  

  • 9. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
    Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C
    Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506
    [No Abstract]   [Full Text] [Related]  

  • 11. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
    Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
    Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
    J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
    Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
    J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
    J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.